Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 10 results out of 10

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

ZEN-3694 by Zenith Epigenetics for Solid Tumor: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ZEN-3694 in Solid Tumor

Data Insights

ZEN-3694 by Zenith Epigenetics for Melanoma: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Data Insights

ZEN-3694 by Zenith Epigenetics for Unspecified B-Cell Lymphomas: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Unspecified B-Cell Lymphomas. According to GlobalData,...

Data Insights

ZEN-3694 by Zenith Epigenetics for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma): Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for NUT Midline Carcinoma (NMC or Nuclear...

Data Insights

ZEN-3694 by Zenith Epigenetics for Epithelial Ovarian Cancer: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...

Data Insights

ZEN-3694 by Zenith Epigenetics for Peritoneal Cancer: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...

Data Insights

ZEN-3694 by Zenith Epigenetics for Fallopian Tube Cancer: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...

Data Insights

ZEN-3694 by Zenith Epigenetics for T-Cell Lymphomas: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...

Data Insights

ZEN-3694 by Zenith Epigenetics for Pancreatic Cancer: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

ZEN-3694 by Zenith Epigenetics for Ovarian Cancer: Likelihood of Approval

ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...